Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound

World Journal of Gastroenterology

Volumn 18, Issue 6, 2012, Pages 541-545

  Schirin Sokhan, Ramin ^a   Winograd, Ron ^a   Roderburg, Christoph ^a   Bubenzer, Jhenee ^a   Nicole Cabral do, O ^a   Guggenberge, Dorothee ^b   Hecker, Hartmut ^c   Trautwein, Christian ^a   Tischendorf, Jens J W ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b Oncological Medical Practice   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Bevacizumab; Colorectal cancer; Contrast enhanced ultrasound; Liver metastases; Response prediction to chemotherapy

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTRAST ENHANCED ULTRASOUND; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; LIVER; LIVER METASTASIS; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; ULTRASOUND;

EID: 84857027817     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v18.i6.541     Document Type: Article

References (13)

1. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782
2. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, Kunstlinger F, Levi F, Bismuth F. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8: 347-353
3. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg; 19: 59-71
4. Power DG, Kemeny NE. Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol 2010; 28: 2300-2309
5. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240: 1052-1061; discussion 1052-1061
6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
7. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65
8. Malavasi N, Ponti G, Depenni R, Bertolini F, Zironi S, Luppi G, Conte PF. Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report. J Hematol Oncol 2009; 2: 35
9. de Geus-Oei LF, van Laarhoven HW, Visser EP, Hermsen R, van Hoorn BA, Kamm YJ, Krabbe PF, Corstens FH, Punt CJ, Oyen WJ. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol 2008; 19: 348-352
10. Byström P, Berglund A, Garske U, Jacobsson H, Sundin A, Nygren P, Frödin JE, Glimelius B. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol 2009; 20: 1057-1061
11. Strobel D, K Seitz, W Blank, A Schuler, C Dietrich, A von Herbay, M Friedrich-Rust, G Kunze, D Becker, U Will, W Kratzer, FW Albert, C Pachmann, K Dirks, H Strunk, C Greis, T Bernatik. Contrast-enhanced ultrasound for the characterization of focal liver lesions--diagnostic accuracy in clinical practice (DEGUM multicenter trial). Ultraschall Med 2008; 29: 499-505
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247
13. Varallyay CG, Muldoon LL, Gahramanov S, Wu YJ, Goodman JA, Li X, Pike MM, Neuwelt EA. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab 2009; 29: 853-860